• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PTX
Click for more information
7.69% 4.2¢

PRESCIENT THERAPEUTICS LIMITED - Announcements

Market Cap $32.21M  ! watchlist Created with Sketch. Add to my watchlist

Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The... Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The Company is developing personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 has completed Phase Ib expansion cohort study in relapsed and refractory T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. OmniCAR is a universal immune receptor platform being developed to enable controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M technology enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumors. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumor microenvironment.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
PTX Notice of General Meeting/Proxy Form27/03/19
PTX Amended Appendix 3B - Rights Issue27/03/19
PTX Change of Director's Interest Notice - J Campbell26/03/19
PTX Letter to Optionholders25/03/19
PTX Letter to Ineligible shareholders25/03/19
PTX Letter to Eligible Shareholders25/03/19
PTX Appendix 3B - Rights Issue25/03/19
PTX ProspectusPRICE SENSITIVE25/03/19
PTX Capital Raising Presentation - March 2019PRICE SENSITIVE25/03/19
PTX Prescient Completes Equity Raising to Raise $9.1 MillionPRICE SENSITIVE25/03/19
PTX Trading HaltPRICE SENSITIVE21/03/19
PTX Investor Presentation - February 201925/02/19
PTX Appendix 4D and Half Year Financial ReportPRICE SENSITIVE21/02/19
PTX December 2018 Appendix 4C - QuarterlyPRICE SENSITIVE31/01/19
PTX Receipt of R&D Tax RebatePRICE SENSITIVE15/01/19
PTX Change of Director's Interest Notice19/12/18
PTX Appendix 3B19/12/18
PTX Change in substantial holding12/12/18
PTX Interim Durability Analysis of PTX-200 Breast Cancer StudyPRICE SENSITIVE10/12/18
PTX Results of Annual General Meeting20/11/18
PTX AGM Presentation20/11/18
PTX Change of Director's Interest Notices x309/11/18
PTX September 2018 Appendix 4C - QuarterlyPRICE SENSITIVE31/10/18
PTX PTX Appoints Former Array BioPharma Executive to Key Role29/10/18
PTX Annual Report to Shareholders19/10/18
PTX Notice of Annual General Meeting/Proxy Form19/10/18
PTX Pipeline Collaboration for Next Generation FormulationsPRICE SENSITIVE17/10/18
PTX Change of Registry Address: Automic P/L - Sydney Office28/09/18
PTX Canadian Patent Granted for PTX-200PRICE SENSITIVE24/09/18
PTX Rodman & Renshaw Global Investment Conference Presentation05/09/18
PTX PTX to present at Rodman & Renshaw Investment conference04/09/18
PTX Release of Securities from Escrow03/09/18
PTX Improved manufacturing route for PTX-100PRICE SENSITIVE03/09/18
PTX Appendix 4G and Corporate Governance Statement31/08/18
PTX Appendix 4E and 2018 Annual ReportPRICE SENSITIVE31/08/18
PTX PTX-200 AML Study ExpandedPRICE SENSITIVE30/08/18
PTX Change in substantial holding15/08/18
PTX June 2018 Appendix 4C - QuarterlyPRICE SENSITIVE31/07/18
PTX US Patent Granted for PTX-200 for Ovarian Cancer TreatmentPRICE SENSITIVE26/07/18
PTX Change of Director's Interest Notices x206/07/18
PTX Appendix 3B05/07/18
PTX PTXO Options Update03/07/18
PTX Appendix 3B22/06/18
PTX Letter to PTXO Option Holders31/05/18
PTX Section 708A Cleansing Notice and Appendix 3B11/05/18
PTX CSO Precision Medicine Presentation01/05/18
PTX March 2018 Appendix 4C - QuarterlyPRICE SENSITIVE23/04/18
PTX Response to Aware QueryPRICE SENSITIVE12/04/18
PTX PTX-200 Phase 1b Breast Cancer Trial ResultsPRICE SENSITIVE10/04/18
PTX Appendix 3B06/04/18
PTX March 2018 Investor PresentationPRICE SENSITIVE19/03/18
PTX Section 708A Cleansing Notice and Appendix 3B14/03/18
PTX Appendix 4D and Half Year Financial ReportPRICE SENSITIVE27/02/18
PTX Receipt of R&D Tax RebatePRICE SENSITIVE01/02/18
PTX December 2017 Appendix 4C - QuarterlyPRICE SENSITIVE31/01/18
PTX Clinical Trial UpdatesPRICE SENSITIVE29/01/18
PTX Prescient Presenting at Biotech Showcase10/01/18
PTX CSO named among Top 20 Translational Researchers by Nature20/12/17
PTX Clinical Hold Lifted on PTX-200 Breast Cancer TrialPRICE SENSITIVE11/12/17
PTX Edison Investment Research - Clinical Development Update21/11/17
PTX Results of Annual General Meeting20/11/17
PTX AGM Chairman Address20/11/17
PTX AGM Presentation20/11/17
PTX PTX to resume Clinical Trial of PTX-200 in Ovarian CancerPRICE SENSITIVE06/11/17
PTX September 2017 Appendix 4C - QuarterlyPRICE SENSITIVE27/10/17
PTX Notice of Annual General Meeting/Proxy Form20/10/17
PTX Investor Presentation - October 201705/10/17
PTX PTX-100 to Re-enter Trials in Hematology NichePRICE SENSITIVE03/10/17
PTX Prescient to resume AML trialPRICE SENSITIVE04/09/17
PTX Appendix 4G and Corporate Governance Statement29/08/17
PTX Appendix 4E and 2017 Annual ReportPRICE SENSITIVE29/08/17
PTX Investor Newsletter - August 201701/08/17
PTX June 2017 Appendix 4C - QuarterlyPRICE SENSITIVE26/07/17
PTX Paul Hopper moves to Non-Executive Director30/06/17
PTX Gold Coast Investor Conference Presentation22/06/17
PTX Novel PTX-100 Cancer Approach Published in NaturePRICE SENSITIVE19/06/17
PTX Appendix 3B31/05/17
PTX Clinical Trial UpdatePRICE SENSITIVE29/05/17
PTX PTX Broker PresentationPRICE SENSITIVE16/05/17
PTX European Patent Granted for PTX-200PRICE SENSITIVE12/05/17
PTX Kansas University Joins PTX's AML TrialPRICE SENSITIVE08/05/17
PTX FDA Grants Orphan Drug Designation for PTX-200 in AMLPRICE SENSITIVE01/05/17
PTX March 2017 Appendix 4C - QuarterlyPRICE SENSITIVE27/04/17
PTX AML Update - Conference call with Principal Investigator20/04/17
PTX Successful Completion of Phase 1b Breast Cancer TrialPRICE SENSITIVE06/04/17
PTX Trading HaltPRICE SENSITIVE04/04/17
PTX Response to ASX Price QueryPRICE SENSITIVE28/03/17
PTX Three Additional US Patents GrantedPRICE SENSITIVE16/03/17
PTX ROTH Conference Presentation15/03/17
PTX PTX presentation for 29th Annual ROTH Conference15/03/17
PTX First Cohort Successfully Completed in Phase 1b/2 AML TrialPRICE SENSITIVE08/03/17
PTX PTX to present at 29th Annual ROTH Conference03/03/17
PTX Appendix 4D and Half Year Financial ReportPRICE SENSITIVE23/02/17
PTX December 2016 Appendix 4C - QuarterlyPRICE SENSITIVE25/01/17
PTX Investor Presentation January 201711/01/17
PTX PTX to present at Biotech Showcase 2017 in San Francisco11/01/17
PTX Change of Director's Interest Notices x421/12/16
PTX Section 708A Cleansing Notice and Appendix 3B21/12/16
PTX Change of Registry Address16/12/16
PTX First Patient Dosed on Phase 1b/2 AML TrialPRICE SENSITIVE14/12/16
PTX Notice of General Meeting/Proxy Form
27/03/19
PTX Amended Appendix 3B - Rights Issue
27/03/19
PTX Change of Director's Interest Notice - J Campbell
26/03/19
PTX Letter to Optionholders
25/03/19
PTX Letter to Ineligible shareholders
25/03/19
PTX Letter to Eligible Shareholders
25/03/19
PTX Appendix 3B - Rights Issue
25/03/19
PTX Prospectus
25/03/19PRICE SENSITIVE
PTX Capital Raising Presentation - March 2019
25/03/19PRICE SENSITIVE
PTX Prescient Completes Equity Raising to Raise $9.1 Million
25/03/19PRICE SENSITIVE
PTX Trading Halt
21/03/19PRICE SENSITIVE
PTX Investor Presentation - February 2019
25/02/19
PTX Appendix 4D and Half Year Financial Report
21/02/19PRICE SENSITIVE
PTX December 2018 Appendix 4C - Quarterly
31/01/19PRICE SENSITIVE
PTX Receipt of R&D Tax Rebate
15/01/19PRICE SENSITIVE
PTX Change of Director's Interest Notice
19/12/18
PTX Appendix 3B
19/12/18
PTX Change in substantial holding
12/12/18
PTX Interim Durability Analysis of PTX-200 Breast Cancer Study
10/12/18PRICE SENSITIVE
PTX Results of Annual General Meeting
20/11/18
PTX AGM Presentation
20/11/18
PTX Change of Director's Interest Notices x3
09/11/18
PTX September 2018 Appendix 4C - Quarterly
31/10/18PRICE SENSITIVE
PTX PTX Appoints Former Array BioPharma Executive to Key Role
29/10/18
PTX Annual Report to Shareholders
19/10/18
PTX Notice of Annual General Meeting/Proxy Form
19/10/18
PTX Pipeline Collaboration for Next Generation Formulations
17/10/18PRICE SENSITIVE
PTX Change of Registry Address: Automic P/L - Sydney Office
28/09/18
PTX Canadian Patent Granted for PTX-200
24/09/18PRICE SENSITIVE
PTX Rodman & Renshaw Global Investment Conference Presentation
05/09/18
PTX PTX to present at Rodman & Renshaw Investment conference
04/09/18
PTX Release of Securities from Escrow
03/09/18
PTX Improved manufacturing route for PTX-100
03/09/18PRICE SENSITIVE
PTX Appendix 4G and Corporate Governance Statement
31/08/18
PTX Appendix 4E and 2018 Annual Report
31/08/18PRICE SENSITIVE
PTX PTX-200 AML Study Expanded
30/08/18PRICE SENSITIVE
PTX Change in substantial holding
15/08/18
PTX June 2018 Appendix 4C - Quarterly
31/07/18PRICE SENSITIVE
PTX US Patent Granted for PTX-200 for Ovarian Cancer Treatment
26/07/18PRICE SENSITIVE
PTX Change of Director's Interest Notices x2
06/07/18
PTX Appendix 3B
05/07/18
PTX PTXO Options Update
03/07/18
PTX Appendix 3B
22/06/18
PTX Letter to PTXO Option Holders
31/05/18
PTX Section 708A Cleansing Notice and Appendix 3B
11/05/18
PTX CSO Precision Medicine Presentation
01/05/18
PTX March 2018 Appendix 4C - Quarterly
23/04/18PRICE SENSITIVE
PTX Response to Aware Query
12/04/18PRICE SENSITIVE
PTX PTX-200 Phase 1b Breast Cancer Trial Results
10/04/18PRICE SENSITIVE
PTX Appendix 3B
06/04/18
PTX March 2018 Investor Presentation
19/03/18PRICE SENSITIVE
PTX Section 708A Cleansing Notice and Appendix 3B
14/03/18
PTX Appendix 4D and Half Year Financial Report
27/02/18PRICE SENSITIVE
PTX Receipt of R&D Tax Rebate
01/02/18PRICE SENSITIVE
PTX December 2017 Appendix 4C - Quarterly
31/01/18PRICE SENSITIVE
PTX Clinical Trial Updates
29/01/18PRICE SENSITIVE
PTX Prescient Presenting at Biotech Showcase
10/01/18
PTX CSO named among Top 20 Translational Researchers by Nature
20/12/17
PTX Clinical Hold Lifted on PTX-200 Breast Cancer Trial
11/12/17PRICE SENSITIVE
PTX Edison Investment Research - Clinical Development Update
21/11/17
PTX Results of Annual General Meeting
20/11/17
PTX AGM Chairman Address
20/11/17
PTX AGM Presentation
20/11/17
PTX PTX to resume Clinical Trial of PTX-200 in Ovarian Cancer
06/11/17PRICE SENSITIVE
PTX September 2017 Appendix 4C - Quarterly
27/10/17PRICE SENSITIVE
PTX Notice of Annual General Meeting/Proxy Form
20/10/17
PTX Investor Presentation - October 2017
05/10/17
PTX PTX-100 to Re-enter Trials in Hematology Niche
03/10/17PRICE SENSITIVE
PTX Prescient to resume AML trial
04/09/17PRICE SENSITIVE
PTX Appendix 4G and Corporate Governance Statement
29/08/17
PTX Appendix 4E and 2017 Annual Report
29/08/17PRICE SENSITIVE
PTX Investor Newsletter - August 2017
01/08/17
PTX June 2017 Appendix 4C - Quarterly
26/07/17PRICE SENSITIVE
PTX Paul Hopper moves to Non-Executive Director
30/06/17
PTX Gold Coast Investor Conference Presentation
22/06/17
PTX Novel PTX-100 Cancer Approach Published in Nature
19/06/17PRICE SENSITIVE
PTX Appendix 3B
31/05/17
PTX Clinical Trial Update
29/05/17PRICE SENSITIVE
PTX PTX Broker Presentation
16/05/17PRICE SENSITIVE
PTX European Patent Granted for PTX-200
12/05/17PRICE SENSITIVE
PTX Kansas University Joins PTX's AML Trial
08/05/17PRICE SENSITIVE
PTX FDA Grants Orphan Drug Designation for PTX-200 in AML
01/05/17PRICE SENSITIVE
PTX March 2017 Appendix 4C - Quarterly
27/04/17PRICE SENSITIVE
PTX AML Update - Conference call with Principal Investigator
20/04/17
PTX Successful Completion of Phase 1b Breast Cancer Trial
06/04/17PRICE SENSITIVE
PTX Trading Halt
04/04/17PRICE SENSITIVE
PTX Response to ASX Price Query
28/03/17PRICE SENSITIVE
PTX Three Additional US Patents Granted
16/03/17PRICE SENSITIVE
PTX ROTH Conference Presentation
15/03/17
PTX PTX presentation for 29th Annual ROTH Conference
15/03/17
PTX First Cohort Successfully Completed in Phase 1b/2 AML Trial
08/03/17PRICE SENSITIVE
PTX PTX to present at 29th Annual ROTH Conference
03/03/17
PTX Appendix 4D and Half Year Financial Report
23/02/17PRICE SENSITIVE
PTX December 2016 Appendix 4C - Quarterly
25/01/17PRICE SENSITIVE
PTX Investor Presentation January 2017
11/01/17
PTX PTX to present at Biotech Showcase 2017 in San Francisco
11/01/17
PTX Change of Director's Interest Notices x4
21/12/16
PTX Section 708A Cleansing Notice and Appendix 3B
21/12/16
PTX Change of Registry Address
16/12/16
PTX First Patient Dosed on Phase 1b/2 AML Trial
14/12/16PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
4.2¢ 		Change
0.003(7.69%) 		Mkt cap ! $32.21M
Open High Low Value Volume
4.0¢ 4.2¢ 4.0¢ $75.86K 1.847M

Buyers (Bids)

No. Vol. Price($)
11 642553 4.2¢
 

Sellers (Offers)

Price($) Vol. No.
4.3¢ 115000 2
View Market Depth
Last trade - 15.17pm 03/12/2024 (20 minute delay) ?
Last
4.2¢ 		  Change
0.003 ( 7.69 %)
Open High Low Volume
3.9¢ 4.2¢ 3.9¢ 166124
Last updated 14.30pm 03/12/2024 ?
PTX (ASX) Chart

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Breaking news: New opportunities for investors & companies - HotCopper opens to capital raising! Companies can now raise capital through HotCopper! It’s a development allowing a highly cost-effective service to ASX-listed companies, while opening new investment opportunities to investors.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.